Moving the Needle for Oncology Dose Optimization: A Call for Action

Overview

Journal Clin Transl Sci

Specialties Biomedical Engineering
General Medicine

Date 2024 Jun 26

PMID 38923292

Authors

Karthik Venkatakrishnan

Priya Jayachandran

Shirley K Seo

Piet H van der Graaf

John A Wagner

Neeraj Gupta

Affiliations

Soon will be listed here.

References

Gao W, Liu J, Shtylla B, Venkatakrishnan K, Yin D, Shah M . Realizing the promise of Project Optimus: Challenges and emerging opportunities for dose optimization in oncology drug development. CPT Pharmacometrics Syst Pharmacol. 2023; 13(5):691-709. PMC: 11098159. DOI: 10.1002/psp4.13079. View

Takeda K, Komatsu K, Morita S . Bayesian dose-finding phase I trial design incorporating pharmacokinetic assessment in the field of oncology. Pharm Stat. 2018; 17(6):725-733. DOI: 10.1002/pst.1890. View

Ruberg S, Beckers F, Hemmings R, Honig P, Irony T, LaVange L . Application of Bayesian approaches in drug development: starting a virtuous cycle. Nat Rev Drug Discov. 2023; 22(3):235-250. PMC: 9931171. DOI: 10.1038/s41573-023-00638-0. View

Janne P, Kim G, Shaw A, Sridhara R, Pazdur R, McKee A . Dose Finding of Small-Molecule Oncology Drugs: Optimization throughout the Development Life Cycle. Clin Cancer Res. 2016; 22(11):2613-7. DOI: 10.1158/1078-0432.CCR-15-2643. View

Johnson M, Serra Traynor C, Vishwanathan K, Overend P, Hartmaier R, Markovets A . Longitudinal Circulating Tumor DNA Modeling to Predict Disease Progression in First-Line Mutant Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer. Clin Pharmacol Ther. 2023; 115(2):349-360. DOI: 10.1002/cpt.3113. View

Micallef S, Sostelly A, Zhu J, Baverel P, Mercier F . Exposure driven dose escalation design with overdose control: Concept and first real life experience in an oncology phase I trial. Contemp Clin Trials Commun. 2022; 26:100901. PMC: 8851091. DOI: 10.1016/j.conctc.2022.100901. View

Venkatakrishnan K, van der Graaf P . Model-Informed Drug Development: Connecting the Dots With a Totality of Evidence Mindset to Advance Therapeutics. Clin Pharmacol Ther. 2021; 110(5):1147-1154. DOI: 10.1002/cpt.2422. View

Yan F, Thall P, Lu K, Gilbert M, Yuan Y . Phase I-II clinical trial design: a state-of-the-art paradigm for dose finding. Ann Oncol. 2017; 29(3):694-699. PMC: 5888967. DOI: 10.1093/annonc/mdx795. View

Venkatakrishnan K, Cook J . Driving Access to Medicines With a Totality of Evidence Mindset: An Opportunity for Clinical Pharmacology. Clin Pharmacol Ther. 2017; 103(3):373-375. DOI: 10.1002/cpt.926. View

10.

Minasian L, Rosen O, Auclair D, Rahman A, Pazdur R, Schilsky R . Optimizing dosing of oncology drugs. Clin Pharmacol Ther. 2014; 96(5):572-9. DOI: 10.1038/clpt.2014.153. View

11.

Ji Y, Jin J, Hyman D, Kim G, Suri A . Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology. Clin Transl Sci. 2018; 11(4):345-351. PMC: 6039198. DOI: 10.1111/cts.12540. View

12.

Choi S, Valente D, Virone-Oddos A, Mauriac C . Developing a mechanistic translational PK/PD model for a trifunctional NK cell engager to predict the first-in-human dose for acute myeloid leukemia. Clin Transl Sci. 2023; 17(1):e13689. PMC: 10772472. DOI: 10.1111/cts.13689. View

13.

Kurzrock R, Lin C, Wu T, Hobbs B, Pestana MD R, Hong D . Moving Beyond 3+3: The Future of Clinical Trial Design. Am Soc Clin Oncol Educ Book. 2021; 41:e133-e144. DOI: 10.1200/EDBK_319783. View

14.

Gerard E, Zohar S, Thai H, Lorenzato C, Riviere M, Ursino M . Bayesian dose regimen assessment in early phase oncology incorporating pharmacokinetics and pharmacodynamics. Biometrics. 2021; 78(1):300-312. PMC: 9292001. DOI: 10.1111/biom.13433. View

15.

Ryeznik Y, Sverdlov O, Svensson E, Montepiedra G, Hooker A, Wong W . Pharmacometrics meets statistics-A synergy for modern drug development. CPT Pharmacometrics Syst Pharmacol. 2021; 10(10):1134-1149. PMC: 8520751. DOI: 10.1002/psp4.12696. View

16.

Janssen J, Verheijen R, van Duijl T, Lin L, van den Heuvel M, Beijnen J . Longitudinal nonlinear mixed effects modeling of EGFR mutations in ctDNA as predictor of disease progression in treatment of EGFR-mutant non-small cell lung cancer. Clin Transl Sci. 2022; 15(8):1916-1925. PMC: 9372429. DOI: 10.1111/cts.13300. View

17.

Venkatakrishnan K, van der Graaf P . Toward Project Optimus for Oncology Precision Medicine: Multi-Dimensional Dose Optimization Enabled by Quantitative Clinical Pharmacology. Clin Pharmacol Ther. 2022; 112(5):927-932. DOI: 10.1002/cpt.2742. View

18.

Pantoja K, Lanke S, Munafo A, Victor A, Habermehl C, Schueler A . Designing phase I oncology dose escalation using dose-exposure-toxicity models as a complementary approach to model-based dose-toxicity models. CPT Pharmacometrics Syst Pharmacol. 2022; 11(10):1371-1381. PMC: 9574748. DOI: 10.1002/psp4.12851. View

19.

Lemaire V, Bassen D, Reed M, Song R, Khalili S, Lien Y . From Cold to Hot: Changing Perceptions and Future Opportunities for Quantitative Systems Pharmacology Modeling in Cancer Immunotherapy. Clin Pharmacol Ther. 2022; 113(5):963-972. DOI: 10.1002/cpt.2770. View

20.

Hanley M, Diderichsen P, Rich B, Largajolli A, Schindler E, Vorog A . Response-Based Dosing for Ponatinib: Model-Based Analyses of the Dose-Ranging OPTIC Study. Clin Pharmacol Ther. 2023; 114(2):413-422. DOI: 10.1002/cpt.2956. View